MedTrace Logo

MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy

NCT05555537 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-10-18

No results posted yet for this study

Summary

Evaluation of the role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy.

Early detection of the prognosis might help in guiding patients for proper management and treatment strategy.

This may open the door for new drug trials.

Conditions

  • Drug Resistant Epilepsy

Interventions

DIAGNOSTIC_TEST

MiRNA223 and High mobility group box1(HMGB1)

Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-10-01
Completion
2024-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05555537 on ClinicalTrials.gov